[E-Daily Reporter Shin Ha-yeon ] LAMEDITECH Co., Ltd.(462510), a company specializing in laser medical and cosmetic devices, is trading up by more than 8% during the session on news that it has begun the regulatory approval process for the domestic launch of a new laser medical device for hospitals and clinics.
According to MP Doctor on the 7th, as of 9:22 a.m. today, LAMEDITECH Co., Ltd. is trading at 2,990 won, up 8.14% from the previous trading day.
This surge is believed to have been driven by LAMEDITECH Co., Ltd.’s announcement earlier today that it had applied to the Ministry of Food and Drug Safety for medical device approval for its “FX-7000M” laser medical device, designed for use in hospitals and clinics. The company plans to launch the product in the domestic market in the second half of this year as soon as the approval process is complete.
The FX-7000M was developed by LAMEDITECH Co., Ltd. specifically for the clinical environment of hospitals and clinics, drawing on the company’s accumulated laser technology and experience in medical device development. It offers performance and ease of use that meet medical device standards and is designed as a laser platform suitable for a wide range of medical and cosmetic procedures.
With the recent surge in demand for skin improvement procedures—including skin boosters—the market for laser medical devices used in hospitals and clinics is also growing. LAMEDITECH Co., Ltd. has incorporated laser micro-channeling technology into the FX-7000M to reduce pain and accelerate recovery, enabling its use in a wide range of medical aesthetic procedures.
The company expects that using the FX-7000M in conjunction with its ECM-based aesthetic solutions currently under development will also help improve drug delivery efficiency. Through this, the company aims to enhance synergies between laser medical devices and aesthetic solutions and expand its product portfolio in the medical aesthetics field.
LAMEDITECH Co., Ltd. stated, “The FX-7000M is a new laser medical device developed to meet the demand in the medical aesthetics market, which is centered on hospitals and clinics,” adding, “We plan to launch it in the domestic market in the second half of this year as soon as approval from the Ministry of Food and Drug Safety is granted, and to expand our market presence into various medical aesthetics treatment settings.”